João Honorato de Araujo-Neto, Adriana P. M. Guedes, Celisnolia M. Leite, Carlos André F. Moraes, Andressa L. Santos, Rafaella da S. Brito, Thiago L. Rocha, Francyelli Mello-Andrade, Javier Ellena, Alzir A. Batista,
Upon exploration of the chemistry of the combination of ruthenium/arene with anthraquinone alizarin (L), three new complexes with the general formulas [Ru(L)Cl(η6-p-cymene)] (C1), [Ru(L)(η6-p-cymene)(PPh3)]PF6 (C2), and [Ru(L)(η6-p-cymene)(PEt3)]PF6 (C3) were synthesized and characterized using spectroscopic techniques (mass, IR, and 1D and 2D NMR), molar conductivity, elemental analysis, and X-ray diffraction. Complex C1 exhibited fluorescence, such as free alizarin, while in C2 and C3, the emission was probably quenched by monophosphines and the crystallographic data showed that hydrophobic interactions are predominant in intermolecular contacts. The cytotoxicity of the complexes was evaluated in the MDA-MB-231 (triple-negative breast cancer), MCF-7 (breast cancer), and A549 (lung) tumor cell lines and MCF-10A (breast) and MRC-5 (lung) nontumor cell lines. Complexes C1 and C2 were more selective to the breast tumor cell lines, and C2 was the most cytotoxic (IC50 = 6.5 μM for MDA-MB-231). In addition, compound C1 performs a covalent interaction with DNA, while C2 and C3 present only weak interactions; however, internalization studies by flow cytometry and confocal microscopy showed that complex C1 does not accumulate in viable MDA-MB-231 cells and is detected in the cytoplasm only after cell permeabilization. Investigations of the mechanism of action of the complexes indicate that C2 promotes cell cycle arrest in the Sub-G1 phase in MDA-MB-231, inhibits its colony formation, and has a possible antimetastatic action, impeding cell migration in the wound-healing experiment (13% of wound healing in 24 h). The in vivo toxicological experiments with zebrafish indicate that C1 and C3 exhibit the most zebrafish embryo developmental toxicity (inhibition of spontaneous movements and heartbeats), while C2, the most promising anticancer drug in the in vitro preclinical tests, revealed the lowest toxicity in in vivo preclinical screening.
https://doi.org/10.1021/acs.inorgchem.3c00183
@article{de_Araujo_Neto_2023, doi = {10.1021/acs.inorgchem.3c00183}, url = {https://doi.org/10.1021%2Facs.inorgchem.3c00183}, year = 2023, month = {apr}, publisher = {American Chemical Society ({ACS})}, volume = {62}, number = {18}, pages = {6955--6969}, author = {Jo{\~{a}}o Honorato de Araujo-Neto and Adriana P. M. Guedes and Celisnolia M. Leite and Carlos Andr{\'{e}} F. Moraes and Andressa L. Santos and Rafaella da S. Brito and Thiago L. Rocha and Francyelli Mello-Andrade and Javier Ellena and Alzir A. Batista}, title = {{\textquotedblleft}Half-Sandwich{\textquotedblright} Ruthenium Complexes with Alizarin as Anticancer Agents: $\less$i$\greater$In Vitro$\less$/i$\greater$ and $\less$i$\greater$In Vivo$\less$/i$\greater$ Studies}, journal = {Inorganic Chemistry} }